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OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has
recently emerged as an important target for molecular therapeutics. The KRAS oncogene also plays an important
role in the development of lung cancer. The aim of this study was to evaluate the frequency of epidermal growth
factor receptor and KRAS mutations in a population of Brazilian patients with non-small cell lung cancer.
METHODS: A total of 207 specimens from Brazilian patients with non-small cell lung cancer were analyzed for
activating epidermal growth factor receptor and KRAS somatic mutations, and their associations with
clinicopathological characteristics (including age, gender, ethnicity, smoking habits, and histological subtype) were
examined.
RESULTS: We identified 63 cases (30.4%) with epidermal growth factor receptor mutations and 30 cases (14.6%)
with KRAS mutations. The most frequent epidermal growth factor receptor mutation we detected was a deletion in
exon 19 (60.3%, 38 patients), followed by an L858R amino acid substitution in exon 21 (27%, 17 patients). The most
common types of KRAS mutations were found in codon 12. There were no significant differences in epidermal
growth factor receptor or KRAS mutations by gender or primary versus metastatic lung cancer. There was a higher
prevalence of KRAS mutations in the non-Asian patients. Epidermal growth factor receptor mutations were more
prevalent in adenocarcinomas than in non-adenocarcinoma histological types. Being a non-smoker was significantly
associated with the prevalence of epidermal growth factor receptor mutations, but the prevalence of KRAS
mutations was significantly associated with smoking.
CONCLUSIONS: This study is the first to examine the prevalence of epidermal growth factor receptor and KRAS
mutations in a Brazilian population sample with non-small cell lung cancer.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related death
in the world, accounting for more than one million deaths
each year (1,2). Non-small cell lung carcinoma (NSCLC) is
the primary subtype. It represents approximately 85% of all
lung cancers and is classified into three histological
subtypes: adenocarcinoma, squamous cell carcinoma, and
large-cell carcinoma (3). Most patients in developed and
underdeveloped countries with NSCLC are diagnosed with
locally advanced metastatic disease (stages III-IV). Cytotoxic
chemotherapy has made a considerable contribution to lung
cancer treatment but has had little impact on patient
survival. Despite regimens that include multiple treatment
modalities, including surgery, radiation, and chemotherapy,
the five-year overall survival rate is less than 14%,
emphasizing the unsatisfactory clinical responses to the
currently available treatments (4). Consequently, the prog-
nosis remains poor for patients with locally advanced
NSCLC and as low as three percent for patients with
metastatic disease (5).
Epidermal growth factor receptor (EGFR) is critically
involved in NSCLC pathogenesis and has recently emerged
as an important target for molecular therapeutics. Two
small-molecule EGFR tyrosine kinase inhibitors, gefitinib
and erlotinib, have demonstrated good potential for treating
lung cancer (6,7). Somatically active EGFR mutations are
involved in the pathogenesis of a considerable subset of
lung adenocarcinomas and sensitize these tumors to
gefitinib and erlotinib treatment. In fact, when patients
with EGFR mutations are treated with one of these agents,
almost all have better progression-free survival than
similarly treated patients with no EGFR mutations (7-9).
This important association has led to the routine use of
molecular tests to identify the lung cancer patients who
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419harbor EGFR mutations before initiating first-line therapy
with tyrosine kinase inhibitors. KRAS mutations are found
in 15 to 25% of lung cancer patients (10). KRAS is
downstream in the EGFR tyrosine kinase pathway; there-
fore, tyrosine kinase-based treatment with gefitinib and
erlotinib is ineffective when KRAS is constitutively acti-
vated (11,12).
Lung cancers with EGFR mutations are prevalent among
young female patients, non-smokers with adenocarcinomas
and Asians (9,13). The frequency of EGFR mutations varies
from 27 to 60% in Asians, from 8 to 13% in Europeans, and
from 12 to 16% in African and white Americans (14,15).
EGFR mutations occur most frequently in exons 18 to 21.
The most common mutations, small in-frame deletions in
exon 19 (.50%) and L858R substitutions in exon 21 (40%),
are reported to be the most closely associated with EGFR
inhibitor therapy response (16,17). By contrast, KRAS
mutations are strongly associated with smoking, and similar
to EGFR mutations, their frequency varies by ethnicity. In
Caucasians, 20 to 30% of lung adenocarcinomas harbor
KRAS mutations, as opposed to 5 to 20% of lung
adenocarcinomas in Asians (18). Approximately 97% of
NSCLC KRAS mutations involve codons 12 and 13 of exon 2
(19). Interestingly, somatic EGFR and KRAS mutations are
almost always mutually exclusive (20).
To the best of our knowledge, there are no data reporting
the joint frequency of EGFR and KRAS mutations in any
South American population. In the present study, we sought
to evaluate the frequency of EGFR and KRAS mutations in a
series of Brazilian patients with lung cancer and to assess
the association between these mutations and clinicopatho-
logical characteristics.
MATERIALS AND METHODS
Patient selection
A total of 207 formalin-fixed, paraffin-embedded speci-
mens from Brazilian patients with lung cancer were
obtained from the files of the Consultoria em Patologia,a
large reference pathology laboratory located in Botucatu,
State of Sa ˜o Paulo, Brazil, from May 2007 to March 2011. All
of the specimens were sent to the reference laboratory
specifically for EGFR and KRAS mutation analysis. In all of
the specimens, either EGFR and KRAS mutations were
detected or the four EGFR exons (18,19,20,21) and exon 2
(codons 2 and 3) of KRAS were analyzed and included in
this study. All five geographic regions of Brazil (56.5% from
the Southeast, 15.5% from the Northeast, 14.5% from the
South, 12.1% from the Midwest, and 1.4% from the North)
were represented in the selected cases.
Hematoxylin and eosin (H&E) staining, and mucicarmine
and/or PAS with diastase staining when necessary, was
performed on 5-mm sections from all of the representative
paraffin blocks and reviewed by two pathologists (CEB and
EMQ). The tumors were then histologically classified
according to 2004 WHO criteria (3). Clinical information,
including age, gender, ethnicity, and smoking habits, was
obtained from pathology requests directly to the patient’s
physician and/or from the pathologists involved in the
original diagnoses.
This study was approved by the Department of Pathology
Scientific Committee of the University of Sao Paulo School
of Medicine and by the Ethical Committee for Research
Projects of the Hospital das Clinicas da Universidade de Sa ˜o
Paulo (‘‘Comissa ˜od eE ´tica para Analise de Projetos de
Pesquisa’’, CAPPesq, protocol #118/11).
DNA extraction and mutational analysis of EGFR
and KRAS
The H&E stained sections of all the tumor specimens
underwent microdissection prior to DNA extraction from
the formalin-fixed embedded tissues. DNA was extracted
from the selected areas using the saline method. Exons 18,
19, 20, and 21 of the EGFR gene and exon 2 of the KRAS gene
were amplified using PCR (Polymerase Chain Reaction).
The primers used have been previously described by
Shigematsu et al. (21). The PCR was performed in 25-mL
reactions containing 100 ng of DNA, 100-mM Tris-HCl, 500-
mM KCl (pH 8.3), 2-mM MgCl2, 0.2-mM dNTPs, 0.15 mMo f
each primer, and 1 U of platinum Taq polymerase. The PCR
reaction was performed on a PTC-200 MJ Research Thermal
Cycler. The initial denaturation at 94˚C for five minutes was
followed by forty cycles of denaturation at 94˚C for sixty
seconds, annealing at 60˚C for thirty seconds, and extension
at 72˚C for sixty seconds, with a final extension step of five
minutes at 72˚C. The amplified DNA was electrophoresed
on a 7% polyacrylamide gel. The PCR products were
sequenced directly in both directions using the BigDyeH
Terminator v3.1 (Applied Biosystems, Foster City, CA)
sequencing ready reaction kit on the ABI PRISMH 3100
Genetic Analyzer (Applied Biosystems, Foster City, CA).
Subsequent sequence analyses were performed using the
Mutation Surveyor v3.9 (SoftGenetics, State College, PA,
USA) and visual inspection. KRAS mutations (exon 2 and
codons 12 and 13) were also detected using real-time PCR
allelic discrimination. The PCR amplification was per-
formed in 5-mL reactions with 5 ng of template DNA, 1x
TaqMan Universal Master Mix (Applied Biosystems, Foster
City, CA), 1x of each primer and a probe assay (Custom
TaqmanH SNP Genotyping assays), and H2O q.s.p. The
thermal cycling was initiated with a denaturation step of ten
minutes at 95˚C, followed by 40 cycles of denaturation at
95˚C for 15 seconds and annealing at 60˚C for one minute on
a 7500 Fast Real-Time System (Applied Biosystems, Foster
City, CA).
Statistical analysis
The EGFR and KRAS mutation frequencies were com-
pared using a proportions test with the normal approxima-
tion. The potential associations of EGFR and KRAS
mutations with gender, ethnicity, smoking status, tumor
histological subtype (adenocarcinomas versus non-adeno-
carcinoma), and metastatic versus primary tumors were
analyzed using Chi-square statistics. A p-value less than
0.05 was considered to be statistically significant.
RESULTS
Clinicopathological characteristics of the patients
This series included 87 men and 120 women, and
information on smoking habits was obtained for 162
patients (88 never-smokers and 74 current and ex-smokers).
The study included 13 Asian and 194 non-Asian patients.
One hundred sixty-nine cases were histologically classified
as adenocarcinomas, and 38 cases were of non-adenocarci-
noma types. One hundred sixty-one cases were primary
tumors, and four were metastatic lung cancers.
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Mutations
The EGFR and KRAS mutational analyses were per-
formed on 207 and 206 cases, respectively. Overall, 63 cases
(30.4%) with EGFR mutations were identified, and 30 cases
(14.6%) with KRAS mutations were identified. No cases of
concomitant EGFR and KRAS mutations were identified.
The most frequent EGFR mutation was an exon 19 deletion
(60.3%, 38 patients), followed by an L858R amino acid
substitution in exon 21 (27%, 17 patients). The following
minor EGFR alterations were also detected: point mutations
at codon 719 in exon 18 (7.9%, five patients); in-frame
insertion mutations in exon 20 (4.8%, three patients); and
one case with an L861Q substitution in exon 21. The most
common KRAS mutations were observed in codon 12: G12C
[GGC.TGT] in 15 cases (50%) and G12D [GGT.GAT] in 6
cases (20%).
Association of EGFR and KRAS mutations with
clinicopathological factors
Information on patient age was obtained in 196 and 195
cases subjected to EGFR and KRAS mutational analysis,
respectively, with a mean age of 62.8(range 25-91). The age of
the subjects was categorized into two groups (.45 and #45
years old) because lung cancer increases with age and
because some studies have shown that EGFR mutations are
more prevalent in younger lung cancer patients (9,13). There
were no differences in the EGFR and KRAS mutational
frequencies between the .45 and #45 year old groups
(Table 1). There were also no statistically significant
differences in gender or primary versus metastatic lung
cancer by EGFR or KRAS mutation status (Tables 2 and 3).
Although the EGFR mutational analyses found no difference
between the Asian and non-Asian patients, KRAS mutations
were much more prevalent in the non-Asian patients. In
fact, all of the KRAS mutations (30 cases) identified were in
non-Asian patients (Table 4). EGFR mutations were more
prevalent in the adenocarcinomas than in the non-adenocar-
cinoma histological subtypes (33.7% versus 15.80%, respec-
tively, Table 5). By contrast, the KRAS mutations did not
differ significantly between these two groups. Smoking
status information was obtained for 162 of the patients with
EGFR mutations and 161 of the patients with KRAS
mutations. Smoking status was significantly associated with
EGFR mutations; 45.5% of the non-smokers had EGFR
mutations, compared with 18.9% of the smokers. In addition,
KRAS mutations were significantly associated smoking; the
frequency of KRAS mutations was 2.7 times higher in the
smokers (Table 6).
DISCUSSION
The EGFR and its ligands are frequently over-expressed
during NSCLC development and progression. The EGFR
regulates important tumorigenic processes, including cell
proliferation, apoptosis, angiogenesis, and invasion (17,22).
In 2004, somatic mutations in the EGFR gene were identified
in a subset of lung adenocarcinomas and were strongly
associated with patient response to the EGFR tyrosine
kinase inhibitors erlotinib and gefitinib (8,9,13). These
studies found an 81% response rate in the patients
harboring EGFR tyrosine kinase mutations (9), while less
than 10% of the patients with wild-type EGFRs responded
(23). By contrast, KRAS mutations have been shown to
predict a poor response to EGFR tyrosine kinase inhibitor
treatment (24).
Table 1 - A comparison of the frequency of EGFR and
KRAS mutations by patient age (.45 and #45 years old).
Mutation Age group (years old) Total
Chi-squared
(p-value)
#45 .45
EGFR No n 13 123 136 1.183 (0.277)
% 59.10% 70.70% 69.40%
Yes n 9 51 60
% 40.90% 29.30% 30.60%
KRAS No n 21 146 167 2.470 (0.116)
% 95.50% 84.40% 85.60%
Yes n 1 27 28
% 4.50% 15.60% 14.40%
Table 2 - A comparison of EGFR and KRAS mutations in
male and female Brazilian lung cancer patients.
Mutation Gender Total
Chi-squared
(p-value)
Male Female
EGFR No n 64 80 144 1.133 (0.287)
% 73.60% 66.70% 69.60%
Yes n2 3 4 0 6 3
% 26.40% 33.30% 30.40%
KRAS No n 72 104 176 0.868 (0.351)
% 82.80% 87.40% 85.40%
Yes n1 5 1 5 3 0
% 17.20% 12.60% 14.60%
Table 3 - A comparison of EGFR and KRAS mutations in
primary and metastatic lung cancers.
Mutation Metastatic Tumor Total
Chi-squared
(p-value)
No Yes
EGFR No n 112 32 144 0.000 (1.000)
% 69.60% 69.60% 69.60%
Yes n 4 91 46 3
% 30.40% 30.40% 30.40%
KRAS No n 139 37 176 1.124 (0.289)
% 86.90% 80.40% 85.40%
Yes n2 1 9 3 0
% 13.10% 19.60% 14.60%
Table 4 - The ethnic distribution (Asian versus non-Asian)
of EGFR and KRAS mutations in Brazilian lung cancer
patients.
Mutation Asian Total
Chi-squared
(p-value)
No Yes
EGFR No n 135 9 144 0.001 (0.978)
% 69.60% 69.20% 69.60%
Yes n5 9 4 6 3
% 30.40% 30.80% 30.40%
KRAS No n 163 13 176 4.239 (0.040)
% 84.50% 100.00% 85.40%
Yes n3 0 3 0
% 15.50% 14.60%
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treatment and its potential side effects, there is an urgent
need to determine the distributions of EGFR and KRAS
mutations in different ethnic populations and perform a
cost-benefit analysis for tyrosine kinase inhibitor treatment.
Numerous clinical trials have confirmed the strong associa-
tion between EGFR tyrosine kinase domain mutations and
response to treatment with EGFR tyrosine kinase inhibitors
in both Western and Asian populations (25). By contrast, the
tyrosine kinase inhibitor response rates of wild-type EGFR
lung tumors have been found to be low.
In the present study, we found that 30.4% (63+/207) and
14.6% (30+/206) of a Brazilian NSCLC patient population
harbored EGFR and KRAS mutations, respectively.
Interestingly, the EGFR mutation rate observed in this
patient population was higher than that described for
Europeans (8-13%) and Americans (10-16%) and close to
the rate observed in Asians (30-50%). Additionally, although
EGFR mutations seem to be associated with East Asian
ethnicity, no geographic associations have been found,
suggesting that EGFR mutations are related to genetic
rather than environmental factors (13,21,26).
Brazil is the fifth largest country in the world. Its
population of approximately 190 million people is distrib-
uted over five large geographic regions (macroregions),
with marked heterogeneity in socioeconomic development,
population density, and climate characteristics. The popula-
tion of Brazil was formed by extensive admixtures between
Amerindians, Europeans, Africans, and Asians. It is one of
the most diverse populations in the world due to five
centuries of ethnic blending involving populations from
three continents. The patients in our study represent all five
geographic regions of Brazil. Their history of ethnic
blending may account for the 30.4% EGFR mutation rate
we found. The 14.6% frequency of KRAS mutations in our
study lies between the frequencies detected in Caucasians
and Asians. In fact, a meta-analysis of 22 studies by Mao et
al. (27) noted that KRAS mutations were detected in 231 of
the 1470 analyzed patients (16%), which is similar to the rate
observed in our study.
In compiled data from multiple publications, 569 muta-
tions were detected in 2880 lung cancer patients. The EGFR
mutations in these studies were distributed as follows:
48.2% in exon 19, 42.7% in exon 21, 3.7% in exon 20, and
3.2% in exon 18 (28). In the present study, the most
frequently detected EGFR mutation was a deletion in exon
19 (60.3%, 38 patients) followed by a L858R substitution in
exon 21 (27%, 17 patients). The most common types of KRAS
mutations we observed were in codon 12: G12C
[GGC.TGT] in 15 (50%) cases and G12D [GGT.GAT] in
6 (20%) cases. Our data on KRAS mutations are consistent
with that from other studies in the literature, in which a
disproportionately high number of cysteine for glycine
changes are described. Cysteine missense substitutions are
the result of a GRT change in the first base of either codon
12 or 13. They have been attributed to the polycyclic
aromatic hydrocarbons that are present in tobacco smoke.
According to several reports in the literature, EGFR lung
cancers are more prevalent among young female patients
who have never smoked, adenocarcinomas, and East Asians
(9,13,21,32). By contrast, KRAS mutations occur mainly in
smokers and adenocarcinoma patients (30,31). We divided
our patients into two groups according to age, .45 and #45,
and found no significant differences between these two
groups for either EGFR or KRAS mutations. Although most
studies have reported that EGFR mutations are more
prevalent in young patients (9,13), others have been unable
to find such an association. Sahoo et al. (32) categorized
their 220 NSCLC Indian patients into three age groups: 20-
40, 40-60, and .60. They found no significant differences in
EGFR mutation prevalence for any of their age groups.
Although we found that EGFR mutations were more
common in females than in males (33.3% versus 26.4%,
respectively), we were unable to detect any significant
differences in the EGFR or KRAS mutation prevalences by
gender. This finding is somewhat inconsistent with most
reported studies, especially for EGFR mutations (21,25).
Studies of EGFR lung tumors in both Western and Asian
populations have consistently found them to be more
common in patients who have never smoked than in
former or current smokers (9,25,33). By contrast, the pooled
results from an analysis of six studies (with a total of 718
NSCLC patients) by Mao et al. (27) found that KRAS
mutations were more common in smokers than in non-
smokers. Our group of NSCLC patients showed similar
associations; EGFR mutations were significantly more
common (45.5%) in non-smokers than in current and ex-
smokers (18.9%), and smokers were 2.7 times more likely to
have a KRAS mutation than were non-smokers. Although
we did not analyze the association between years of
smoking and EGFR mutations, it is well known that the
probability of EGFR mutations is inversely associated with
the number of pack years smoked (25). Additionally, a non-
smoking or low-smoking history is the strongest predictor
of EGFR mutations (34).
Table 5 - The association of histological subtype
(adenocarcinoma versus non-adenocarcinoma) with EGFR
and KRAS mutations in Brazilian lung cancer patients.
Mutation Adenocarcinoma Total
Chi-squared
(p-value)
No Yes
EGFR No n 32 112 144 4.715 (0.030)
% 84.20% 66.30% 69.60%
Yes n 6 57 63
% 15.80% 33.70% 30.40%
KRAS No n 35 141 176 1.886 (0.170)
% 92.10% 83.90% 85.40%
Yes n 3 27 30
% 7.90% 16.10% 14.60%
Table 6 - The association of smoking status (never smoked
versus current or ex-smoker) with EGFR and KRAS
mutations in Brazilian lung cancer patients.
Mutation Smoking Status Total
Chi-squared
(p-value)
No Yes
EGFR No n 48 60 108 12.737
(,0.001)
% 54.50% 81.10% 66.70%
Yes n 4 01 45 4
% 45.50% 18.90% 33.30%
KRAS No n 81 60 141 5.313 (0.020)
% 93.10% 81.10% 87.60%
Yes n 6 14 20
% 6.90% 18.90% 12.40%
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significantly between the Asian and non-Asian patients.
By contrast, KRAS mutations were more common in the
non-Asian patients. In fact, all of the KRAS mutations (30
cases) in our study were detected in non-Asian patients. It is
important to mention that the number of patients with
Asian ancestry in our study may not have been sufficient to
allow detecting a statistically significant difference in the
EGFR mutation frequency by ethnicity.
EGFR mutations in lung cancer patients are strongly
associated with adenocarcinoma histology (21,25,33) and
have been found in no more than 3% of other NSCLC
subtypes (21,35). EGFR mutations were more prevalent
(33.7%) in our Brazilian NSCLC patients with adenocarci-
nomas than in those with other histological subtypes
(15.80%). No significant differences in KRAS mutations
between these two groups were detected. Interestingly, no
more than 3% of the non-adenocarcinoma lung cancer
patients in our study population had EGFR mutations,
which reflects the relative scarcity of this mutation in non-
adenocarcinoma histological subtypes.
Our failure to find any difference in either EGFR or KRAS
mutations by primary versus metastatic lung cancer
indicates that both primary lung tumors and their metas-
tases are suitable specimens for selecting patients for EGFR
tyrosine kinase inhibitor treatment.
In summary, this study is the first to examine the
prevalence of EGFR and KRAS mutations in a South
American population. It consisted of 207 Brazilian NSCLC
patients from all of the geographic regions of Brazil.
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